Our clients include world's top universities and pharmaceutical organizations
PainReform
Wednesday, November 20, 2024
PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial
Lineage Cell Therapeutics
Wednesday, November 20, 2024
Lineage Cell Therapeutics Announces Pricing of up to $66 Million Registered Direct Offering
electroCore
Wednesday, November 20, 2024
electroCore’s Truvaga™ Plus Wins Woman’s World Magazine 50 over 50 Award
Recursion Pharmaceuticals
Wednesday, November 20, 2024
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery
Lancet
Thursday, November 7, 2024
Betibeglogene autotemcel gene therapy in patients with transfusion-dependent, severe genotype β-thalassaemia (HGB-212): a non-randomised, multicentre, single-arm, open-label, single-dose, phase 3 trial
Nature Medicine
Wednesday, November 6, 2024
Collaboration between clinicians and vision–language models in radiology report generation
Nature
Wednesday, November 6, 2024
Evolving antibody response to SARS-CoV-2 antigenic shift from XBB to JN.1
Lancet
Wednesday, November 6, 2024
Disparities in wellbeing in the USA by race and ethnicity, age, sex, and location, 2008–21: an analysis using the Human Development Index
Argenx
Wednesday, November 20, 2024
argenx Advances Clinical Development of Efgartigimod SC in Idiopathic Inflammatory Myopathies
PureTech Health
Wednesday, November 20, 2024
PureTech Founded Entity Seaport Therapeutics Adds Sandi Peterson to its Board of Directors
Ocugen
Wednesday, November 20, 2024
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease
Voyager Therapeutics
Wednesday, November 20, 2024
Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease
Lancet
Wednesday, November 6, 2024
Induced pluripotent stem-cell-derived corneal epithelium for transplant surgery: a single-arm, open-label, first-in-human interventional study in Japan
Nature
Tuesday, November 5, 2024
Coordinated inheritance of extrachromosomal DNAs in cancer cells
Nature
Tuesday, November 5, 2024
Selective ion transport through hydrated micropores in polymer membranes
Nature
Tuesday, November 5, 2024
Autonomous mobile robots for exploratory synthetic chemistry
C4 Therapeutics
Wednesday, November 20, 2024
C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors
Kura Oncology
Wednesday, November 20, 2024
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
Day One Biopharmaceuticals
Wednesday, November 20, 2024
Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development
Karyopharm Therapeutics
Wednesday, November 20, 2024
Karyopharm Therapeutics Announces the Appointment of Chief Accounting Officer
Nature
Tuesday, November 5, 2024
Preferential occurrence of fast radio bursts in massive star-forming galaxies
Nature
Tuesday, November 5, 2024
A cellular basis for mapping behavioural structure
Nature
Tuesday, November 5, 2024
Immune responses in checkpoint myocarditis across heart, blood and tumour
Nature
Tuesday, November 5, 2024
Identification and genetic dissection of convergent persister cell states
Amgen
Wednesday, November 20, 2024
AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT
kyowa Kirin
Wednesday, November 20, 2024
Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
UCB
Tuesday, November 19, 2024
UCB receives U.S. FDA approval for BIMZELX[®] (bimekizumab-bkzx) as the first IL-17A and IL-17F inhibitor for adults with moderate to severe hidradenitis suppurativa
Sangamo Therapeutics
Tuesday, November 19, 2024
Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain
Nature
Tuesday, November 5, 2024
Nucleosome flipping drives kinetic proofreading and processivity by SWR1
Nature
Tuesday, November 5, 2024
Mutant-selective AKT inhibition through lysine targeting and neo-zinc chelation
Nature
Tuesday, November 5, 2024
Stochastic neuropeptide signals compete to calibrate the rate of satiation
Nature
Tuesday, November 5, 2024
A mechanism for hypoxia-induced inflammatory cell death in cancer
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.